Seattle, WA, United States of America

Richard D Holly

USPTO Granted Patents = 34 

 

Average Co-Inventor Count = 4.6

ph-index = 9

Forward Citations = 386(Granted Patents)


Company Filing History:


Years Active: 1994-2013

Loading Chart...
Loading Chart...
34 patents (USPTO):Explore Patents

Title: Richard D. Holly - Innovator in Antibody Research

Introduction

Richard D. Holly is a distinguished inventor based in Seattle, Washington, with an impressive portfolio of 34 patents. His work primarily focuses on the development of antibodies that engage with cytokine zalpha11 ligand, contributing significantly to advancements in therapeutic applications and biotechnology.

Latest Patents

Among his latest contributions are patents related to antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 ligand, specifically detailed in SEQ ID NO: 2. These antibodies can target either the full-length sequence of 162 amino acid residues or various fragments, including a mature polypeptide of 131 amino acid residues and smaller peptide sequences. The range of antibodies includes polyclonal, monoclonal, murine, humanized, and neutralizing variants. In addition, methods for producing these antibodies are described, showcasing his innovative approach to biopharmaceutical development.

Career Highlights

Richard D. Holly has had a noteworthy career, having worked with prominent organizations such as Zymogenetics, Inc. and the University of Washington. His roles in these institutions have catalyzed groundbreaking research and advancements in the field of immunology, particularly in the creation of therapeutic antibodies.

Collaborations

Throughout his career, Richard has collaborated with esteemed colleagues, including Donald C. Foster and Julia E. Novak. These partnerships have fostered a collaborative environment that enhances research outcomes and accelerates innovation in antibody development.

Conclusion

In conclusion, Richard D. Holly's contributions to antibody research, particularly in relation to cytokine zalpha11 ligand, highlight his role as a leading innovator in biotechnology. With numerous patents to his name and a track record of collaboration with key figures in the industry, his work continues to influence the future of therapeutics and antibody applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…